Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

   By Peter Loftus 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

Stocks mentioned in the article : Merck & Co., Inc.
Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.60% 61.51 Delayed Quote.8.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
11:11aMERCK AND : FDA restricts Keytruda, Tecentriq monotherapy
06/21AGILENT TECHNOLOGIES : Companion Diagnostic Gains Expanded FDA Approval in Cervi..
06/21MERCK AND : - Late-Breaking Data to be presented from the Comparative Trials wit..
06/21MERCK AND : CEO Kenneth Frazier, speaking in Philly, urges people to call out 'u..
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
06/18MERCK AND : Late-Breaking Data to be Presented from the Comparative Trials with ..
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
06/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
More news
News from SeekingAlpha
06/21Key events next week - healthcare 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
06/19ALZHEIMER'S DISEASE : A History Of Drug Failures 
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/16Dynavax Gives A Welcome Business Update 
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,19%
P/E ratio 2018 23,55
P/E ratio 2019 15,92
EV / Sales 2018 4,29x
EV / Sales 2019 4,09x
Capitalization 165 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 13%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.27%327 330
PFIZER0.00%213 275
NOVARTIS-10.87%189 575
ROCHE HOLDING LTD.-12.58%188 417
AMGEN7.07%123 415